Recently, the FDA has issued important updates to the Emergency Use Authorizations (EUA) for bamlanivimab and etesevimab (administered together) and REGEN-COV, both treatments that have been authorized for use in cases of COVID-19 with mild to moderate symptoms in patients who meet the criteria for its use. See the latest FDA fact sheet (bamlanivimab and etesevimab) for healthcare professionals.
–
